Rongchang Biological (09995): The phase III clinical study of vedolizumab monotherapy for first-line treatment of HER2-expressing urothelial carcinoma has reached the main study endpoint.

Zhixin Finance APP News, Rongchang Biotech (09995) announced that the company's independently developed antibody drug conjugate (ADC) Vedixituximab (code: RC48, trade name: Aieaxis) in combination with trastuzumab compared to chemotherapy for the first-line local advanced or metastatic HER2-expressing urothelial carcinoma Phase III clinical study (RC48 C016) has achieved the two main study endpoints of progression-free survival (PFS) and overall survival (OS).